Sort
10,766 grants matching “checkpoint inhibitor”
Cyclin-dependent kinase control of cell-division and transcription cycles
$464,704Robert P Fisher · Icahn School Of Medicine At Mount Sinai · R35 · FY2020 · GM
Cyclin-dependent kinase control of cell-division and transcription cycles
$464,704Robert P Fisher · Icahn School Of Medicine At Mount Sinai · R35 · FY2022 · GM
F-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in Cancer
$464,613Michele Pagano · New York University School Of Medicine · R01 · FY2021 · CA
F-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in Cancer
$464,613Michele Pagano · New York University School Of Medicine · R01 · FY2017 · CA
F-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in Cancer
$464,613Michele Pagano · New York University School Of Medicine · R01 · FY2020 · CA
F-Box Proteins: Deregulated Cell Cycle Control and Proteolysis in Cancer
$464,613Michele Pagano · New York University School Of Medicine · R01 · FY2018 · CA
Targeting TERT in Melanoma
$464,587Jessie Villanueva · Wistar Institute · R01 · FY2021 · CA
TLR Agonist Nano-Immune Therapy for Peritoneal Metastases
$464,569Rita Elena Serda · University Of New Mexico Health Scis Ctr · R01 · FY2025 · CA
Novel roles for the DNA damage response kinase CHK1 in TCR/ITAM signaling
$464,560Carrie L. Lucas · Yale University · R01 · FY2019 · AI
Mechanisms and Functions of ATR signaling
$464,467David K Cortez · Vanderbilt University · R01 · FY2023 · CA
Mechanisms and Functions of ATR signaling
$464,467David K Cortez · Vanderbilt University · R01 · FY2022 · CA
Project 4: Translation and preclinical studies of a personalized pancreas cancer vaccine
$464,275William E Gillanders · Washington University · P50 · FY2017 · CA
Targeting autophagy to enhance immune checkpoint inhibition
$464,236Ravi K Amaravadi · Wistar Institute · P50 · FY2024 · CA
Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma
$464,222David Sidransky · Johns Hopkins University · R01 · FY2023 · CA
Project 1- Elucidating oncogenic KRAS in PDAC cell signaling, resistance and immunity
$464,161Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2025 · CA
Immunometabolic pathways enabled by PARP inhibition in breast cancer
$463,884Jennifer L. Guerriero · Brigham And Women'S Hospital · R37 · FY2023 · CA
Developing newly combined therapeutic strategies for mature B cell lymphoma
$463,626Jing Hong Wang · University Of Colorado Denver · R01 · FY2020 · CA
Understanding the effect of aging on the lung adenocarcinoma tumor microenvironment
$463,625Alexander Minchev Tsankov · Icahn School Of Medicine At Mount Sinai · R21 · FY2025 · AG
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
$463,621Judith A. Varner · University Of California, San Diego · R01 · FY2022 · CA
OST Inhibition in NSCLC
$463,580Joseph N Contessa · Yale University · R01 · FY2024 · CA
Preclinical Development of First-in-Class NDUFS7 Antagonists for the Treatment of Pancreatic Cancer
$463,556Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
$463,483Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Modulation of tumor inflammatory factor for immune therapy
$463,463Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2020 · CA
Modulation of tumor inflammatory factor for immune therapy
$463,463Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2021 · CA
Modulation of tumor inflammatory factor for immune therapy
$463,463Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2018 · CA